Home›Cyp Substrates›Cyp Substrates + Talquetamab

Does Cyp Substrates Interact with Talquetamab?

Cyp Substrates and Talquetamab have a major drug interaction according to U.S. FDA drug labeling data. Talquetamab causes cytokine release that may suppress CYP enzyme activity, resulting in increased exposure of CYP substrates. Risk is highest during step-up dosing (up to 14 days after first dose) and during/after cytokine release syndrome. The mechanism involves cytokine-mediated suppression of cyp enzyme activity. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Major
Management
Close medical supervision required
Data Source
U.S. FDA via OpenFDA

How This Interaction Works

The interaction between Cyp Substrates and Talquetamab occurs because cytokine-mediated suppression of cyp enzyme activity. Clinically, this means talquetamab causes cytokine release that may suppress cyp enzyme activity, resulting in increased exposure of cyp substrates. risk is highest during step-up dosing (up to 14 days after first dose) and during/after cytokine release syndrome. This is classified as a major interaction, meaning it could cause serious harm if not properly managed. Your healthcare provider may need to adjust dosages, substitute one medication, or increase monitoring frequency.

What To Tell Your Doctor or Pharmacist

If you are taking Cyp Substrates and your doctor is considering prescribing Talquetamab (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask how frequently you should be monitored while these are co-prescribed
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Cyp Substrates+💊 Talquetamab(Talvey)

Severity & Interaction Details

⚠️
major
Use with caution — major interaction
Serious risk of clinically significant harm. Generally avoid; if used, monitor closely.
Severity scale
MinorContra
On record
Yes
Drug A class
—
Drug B class
—
Source
NLP:talquetamab

What this means in plain English

Talquetamab causes cytokine release that may suppress CYP enzyme activity, resulting in increased exposure of CYP substrates. Risk is highest during step-up dosing (up to 14 days after first dose) and during/after cytokine release syndrome.

What the FDA label says

"Cytokine-mediated suppression of CYP enzyme activity"

📖 Source: NLP:talquetamab

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Cyp Substrates and Talquetamab against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.